Shopping Cart
- Remove All
Your shopping cart is currently empty
Linagliptin Methyldimer
Linagliptin Methyldimer is a potent dipeptidyl peptidase IV inhibitor, IC50=6 pM.
Catalog No. T67852Cas No. 1418133-47-7
Select Batch
Purity:97.23%
Contact us for more batch information
Linagliptin Methyldimer
Catalog No. T67852Cas No. 1418133-47-7
Linagliptin Methyldimer is a potent dipeptidyl peptidase IV inhibitor, IC50=6 pM.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $117 | In Stock | |
| 2 mg | $169 | In Stock | |
| 5 mg | $289 | In Stock | |
| 10 mg | $428 | In Stock | |
| 25 mg | $698 | In Stock | |
| 50 mg | $968 | In Stock | |
| 100 mg | $1,280 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Linagliptin Methyldimer"
4'-Hydroxychalcone
2-Benzal-4-Hydroxyacetophenone
T79172657-25-2
4'-Hydroxychalcone (2-Benzal-4-Hydroxyacetophenone) is a chalcone metabolite with hepatoprotective activity
- $47
Size
QTY
4'-Hydroxychalcone
2-Benzal-4-Hydroxyacetophenone
T79172657-25-2
4'-Hydroxychalcone (2-Benzal-4-Hydroxyacetophenone) is a chalcone metabolite with hepatoprotective activity
- $47
Size
QTY
Sitagliptin
Cited
MK0431
T0242486460-32-6
Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
- $36
Size
QTY
CitedSitagliptin Cited
MK0431
T0242486460-32-6
Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
- $36
Size
QTY
CitedSitagliptin Cited
MK0431
T0242486460-32-6
Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
- $36
Size
QTY
CitedVildagliptin
Cited
NVP-LAF 237, LAF237
T1502274901-16-5
Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.
- $30
Size
QTY
CitedVildagliptin Cited
NVP-LAF 237, LAF237
T1502274901-16-5
Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.
- $30
Size
QTY
CitedVildagliptin Cited
NVP-LAF 237, LAF237
T1502274901-16-5
Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.
- $30
Size
QTY
CitedVildagliptin Cited
NVP-LAF 237, LAF237
T1502274901-16-5
Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.
- $30
Size
QTY
CitedSitagliptin phosphate monohydrate
MK-0431 phosphate monohydrate, MK-0431
T0242L654671-77-9
Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent DPP-IV inhibitor with an IC50 of 19 nM in Caco-2 cell extracts.
- $50
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | Linagliptin Methyldimer is a potent dipeptidyl peptidase IV inhibitor, IC50=6 pM. |
| Targets&IC50 | DPP4:6 pM |
| Molecular Weight | 945.08 |
| Formula | C50H56N16O4 |
| Cas No. | 1418133-47-7 |
Storage & Solubility Information
| Storage | store at low temperature,keep away from direct sunlight | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 9.52mg/mL (10 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Linagliptin Methyldimer | purchase Linagliptin Methyldimer | Linagliptin Methyldimer cost | order Linagliptin Methyldimer | Linagliptin Methyldimer chemical structure | Linagliptin Methyldimer formula | Linagliptin Methyldimer molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.